InspireMD amends warrants, potential $11M proceeds tied to anticipated FDA approval of CGuard Prime 80 cm

InspireMD, Inc.

Amended Series J (4.8M shares) and Series K (9.5M shares) warrants; exercise price for amended portion set at $0.7674.
Potential gross proceeds up to $11M if exercised; no additional warrants issued.
Termination date changed to May 15, 2028 or 20 trading days after FDA approval announcement; approval expected Q4 2026.
Unchanged Series J half retains $1.3827 exercise price and SwitchGuard trigger.
CGuard Prime 80 cm shows 100% acute success, zero MAEs at 30 days in 36-patient study; TCAR market doubles addressable opportunity.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.